^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:HER2 Positive Breast Cancer
    Drug:Perjeta (pertuzumab) (HER2 dimerization inhibitor) +
    Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Breast Cancer Res
    Title:

    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

    Published date:
    01/11/2023
    Excerpt:
    KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer....Mutated versus non-mutated PIK3CA tumors were associated with numerically lower pCR rates in the T-DM1 + P arm but not in the TCH + P arm….
    DOI:
    https://doi.org/10.1186/s13058-022-01587-z
    Trial ID:
    KRISTINE